Petco Health & Wellness Company, Inc. — Form 10-Q Summary
Period: The filing covers the 13 and 26 weeks ended July 29, 2023, compared with the periods ended July 30, 2022. Although the request identifies “2022 Q2,” the filing itself is for fiscal 2023 Q2. Financial statements are unaudited. Petco operates as a single reportable segment, with pet care centers, digital sales, and services including veterinary care and grooming.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Net sales | $1.531 billion | $1.481 billion | $3.087 billion | $2.957 billion |
| Gross profit / margin | $593.0 million / 38.7% | $594.5 million / 40.1% | $1.197 billion / 38.8% | $1.202 billion / 40.7% |
| Operating income / margin | $24.0 million / 1.5% | $50.0 million / 3.3% | $51.7 million / 1.7% | $99.9 million / 3.4% |
| Net income (loss) | $(14.6) million | $13.5 million | $(16.5) million | $37.3 million |
| Adjusted EBITDA / margin | $112.6 million / 7.4% | $133.5 million / 9.0% | $223.6 million / 7.2% | $252.7 million / 8.5% |
Q2 comparable sales increased 3.2% (versus 3.8%); first-half comparable sales rose 4.1% (versus 4.4%). Q2 sales growth reflected consumables (+6.8%) and services and other (+30.6%), partly offset by supplies and companion animals (-9.4%). E-commerce and digital sales grew 9.4% in Q2. Management attributed services growth to membership, grooming, and veterinary activity; service-related sales including veterinary hospitals increased 16.6%.
Cash flow, debt, and liquidity
- First-half operating cash flow was $134.3 million, compared with $100.1 million; capital expenditures were $114.0 million, producing reported free cash flow of $20.2 million versus negative $36.1 million.
- Cash and cash equivalents were $173.0 million at July 29, 2023. Reported liquidity was $619.4 million, including $446.4 million available under the asset-based revolving facility; no revolver borrowings were outstanding.
- First Lien Term Loan principal was $1.610 billion, with a weighted-average interest rate of 8.9% (8.2% at fiscal year-end). The company repaid $60 million during the first half and an additional $15 million in August 2023. First-half interest expense rose to $74.7 million from $41.5 million.
- Management stated that cash, anticipated operating cash flow, and available borrowing capacity should be sufficient for operations and planned capital investment for at least the next 12 months. The company was in compliance with debt covenants.
Key changes, outlook, and risks
- Despite revenue growth, Q2 operating income fell 51.9% and the company moved from net income to a net loss. Gross margin contracted, which management attributed mainly to sales mix—stronger consumables and services and softer supplies—and channel mix.
- SG&A increased 4.5% in Q2, including higher equity-based compensation; Q2 equity compensation was $24.1 million versus $12.9 million. Higher variable interest rates materially increased interest expense and weighed on earnings.
- Management cited inflationary pressures and consumer softness in discretionary products, along with interest rates, supply-chain constraints, and geopolitical and economic developments. Other disclosed risks include competition, vendor dependence, labor, technology and cybersecurity, product quality, and access to capital.
- The filing provides no specific forward financial guidance. Management described continued investment in infrastructure, employees, veterinary hospitals, and other growth initiatives. Interest-rate caps and collars hedge a portion of variable-rate exposure; a 100-basis-point rate increase was estimated to add approximately $16.3 million to annual cash interest before considering hedges.
- Other non-operating results shifted to $1.8 million of income in Q2 from a $10.3 million loss a year earlier; the filing discusses fair-value changes and the sale of the Rover investment. The company recorded $0.7 million of first-half losses on partial debt extinguishments. It reported no goodwill or trade-name impairment trigger, but recorded $1.1 million of first-half fixed-asset and right-of-use-asset impairment charges.
- Management concluded disclosure controls were effective at a reasonable assurance level. The company moved to a cloud-based ERP system during the quarter and modified controls as needed. Ordinary-course legal matters were not considered individually or collectively material by management, though outcomes remain uncertain.
Important facts for investors to verify
- Whether comparable-sales growth and service, veterinary, and digital momentum can offset continued weakness in discretionary merchandise.
- Whether margin and Adjusted EBITDA declines stabilize as sales mix, operating costs, and investment levels change.
- How variable-rate debt costs evolve, how effective the hedges are, and whether planned debt repayments remain affordable.
- Whether operating cash generation continues to cover capital expenditures, lease obligations, interest, and other cash needs.
- The assumptions behind management’s at-least-12-month liquidity assessment, as well as developments in legal matters and the ERP control environment.